Cessatech A/S (NGM:CESSA)

Market Cap	442.10M +46.8%
Revenue (ttm)	8.29M +130.0%
Net Income	-15.80M
EPS	-0.87
Shares Out	18.58M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,228
Average Volume	31,191
Open	16.62
Previous Close	16.60
Day's Range	16.00 - 16.62
52-Week Range	6.00 - 26.00
Beta	0.65
RSI	36.73
Earnings Date	Feb 27, 2026

About Cessatech

Cessatech A/S, a pharmaceutical company, develops and commercializes medicines for the treatment of pediatric acute pain in Denmark. The company’s lead product is CT001, an analgesic nasal spray for the treatment of acute and planned painful procedures in children. It also develops CT002, a nasal spray for sedative procedures for children from 0-17 years of age; and CT003, a local anesthetic gel. The company has a collaboration and license agreement with Ventis Pharma Corporation to develop and formulate pain management therapies. Cessatech A/S...

• Industry: Pharmaceutical Preparations
• Founded: 2020
• Employees: 4
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: CESSA

Financial Performance

In 2025, Cessatech's revenue was 5.72 million, an increase of 130.01% compared to the previous year's 2.49 million. Losses were -10.90 million, -25.67% less than in 2024.

Financial numbers in DKK